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Background: Obese individuals who are not at an elevated risk for cardiovascular disease are described as having
metabolically healthy obesity (MHO). We sought to identify clinically useful indicators of MHO.
Methods: Records of the Korean National Health and Nutrition Examination Survey (2009-2010) were used to
analyze 3,770 obese subjects (body mass index ≥ 25 kg/m2), who were divided into metabolic syndrome and MHO
groups. Persons who met less than 3 of the criteria of metabolic syndrome (MS) were defined as having MHO. We
estimated age-specific prevalence rates according to the number of MS criteria that were satisfied (patients meeting
0, ≤1, and ≤2 criteria of MS). Receiver operating characteristic analysis was performed to identify the best indicators
of MHO.
Results: The prevalence of MHO among obese patients decreased with age. When MHO was defined by the
fulfillment of ≤2 criteria of MS, the areas under the curves (AUC) for waist circumference and waist-to-height ratio
were 0.743 and 0.747 in men and 0.712 and 0.741 in women, respectively. Waist circumference and waist-to-height
ratio were the most accurate predictors of MHO for all investigated definitions.
Conclusions: Waist circumference and waist-to-height ratio provide useful indicators for diagnosing MHO, and are
more accurate than body mass index, fat percentage, or weight-adjusted appendicular skeletal muscle mass in the
Korean population.
Keywords: Metabolically healthy obesity, Waist circumference, Waist height ratio, Body mass indexBackground
As the obese population increases worldwide, the inci-
dence of metabolic syndrome (MS) is also rising. People
who are obese have a higher risk of cardiovascular dis-
ease (CVD) and diabetes [1]. MS is associated with a
higher risk of a variety of diseases and conditions, in-
cluding CVD, insulin resistance, diabetes, hypertension,
and hyperlipidemia [2]. A recent study reported that the
prevalence of MS in Korea was between 4.6% among
teenagers and 25.0% among people in their fifties [3].
Body mass index (BMI) is widely used as an indicator
of obesity, but it has several limitations for assessing* Correspondence: rohyk@hallym.ac.kr
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unless otherwise stated.metabolic or health status, particularly for persons who
would commonly be classified as obese [4]. Indeed, some
individuals with high BMIs are not at excess risk for the
diseases that are generally associated with obesity; these
persons are described as having metabolically healthy
obesity (MHO) [5,6]. Persons with MHO appear to have
lower levels of subcutaneous fat and lipid accumulation
in the liver than persons with other types of obesity, des-
pite similar body fat compositions. Insulin sensitivity,
blood pressure, lipid profiles, and inflammation-related
factors (plasma C-reactive protein) are normal in per-
sons with MHO [7,8]. Further, individuals with MHO
generally exercise more regularly and were much less
likely to smoke than individuals with other types of
obesity. In addition, in an 11-year observational study,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CVD or diabetes than normal-weight comparators [9].
Reports on the prevalence of MHO vary according to
patient characteristics and diagnostic criteria. Studying
an American population, Meigs et al. found that 37.0%
of obese subjects (BMI > 30 kg/m2) did not have meta-
bolic syndrome (MS) or a significantly increased risk of
CVD [9]. Studying an adult Korean population, Lee et al.
found that 47.9% of obese subjects (BMI ≥ 25 kg/m2)
had MHO [10].
The definition of MHO has not been clearly established
thus far, but it is generally identified by blood pressure,
body measurements (such as abdominal circumference),
triglyceride, cholesterol, fasting blood sugar, and homeo-
stasis model assessment [6,11]. However, there is no single
established criterion for MHO, and the incidence rate dif-
fers according to the criteria used in a previously unquan-
tified manner.
Accordingly, in this study, we investigated how the
prevalence of MHO in Korea varied when it was assessed
using different criteria, which were selected from the
5 diagnostic criteria for metabolic syndrome: waist
circumference, blood pressure, fasting blood sugar, trigly-
ceride, and high-density lipoprotein cholesterol. We fur-
ther assessed several indicators of obesity that may be
useful for diagnosing MHO, both in Korea and worldwide:
body mass BMI, waist circumference, weight-adjusted ap-
pendicular skeletal muscle mass (ASM), fat percentage,
and waist-to-height ratio (WtHR).
There has been little previous research on MHO in
Asia, but we expect that separate investigation is necessary
because the definition of obesity varies internationally, for
example being a substantially lower BMI in Korea
(≥25 kg/m2) than in the United States (>30 kg/m2).
Methods
Study subjects
The Korean National Health and Nutrition Examination
Survey (KNHANES) is a community-based, cross sec-
tional survey that is conducted by Division of Chronic
Disease Surveillance of the Korea Centers for Disease
Control and Prevention. We analyzed surveys collected
from 2009 to 2010, representing the third year of the
KNHANES IV (2007–2009) survey and the first year of
the KNHANES V (2010–2012) survey. Associated sam-
pling and data collection procedures have been de-
scribed in detail previously [12]. The January 2009 to
December 2010 survey data comprised 14,633 subjects
aged 20 years or older. Of these, 4,356 subjects had a
BMI ≥ 25 kg/m2, which is the threshold for obesity set
by the World Health Organization Asia Pacific guide-
lines [13]. We excluded participants who had missing
data for dual-energy X-ray absorptiometry (DXA), meta-
bolic, or anthropometric variables that were included inour analysis (n = 495); as well as those who had liver cir-
rhosis, chronic liver disease, or renal disease (n = 40);
and those with malignancies (n = 51). After excluding
the ineligible subjects, the total number of participants
was 3,770 (1,904 were female), which were divided
into MHO and MS groups and analyzed. The protocol
of KNHANES IV and V was approved by the Korea
Centers for Disease Control and Prevention Institution-
alized Review Board. All participants in this survey pro-
vided written informed consent.
Study methods
1) Body Measurements, Obesity Indicators, and
Biochemical Analysis
Height and weight were measured using SECA 225
height rods (SECA, Hamburg, Germany) and GL-6000-
20 scales (CAS, Seoul, Korea), respectively, to the near-
est decimal point. BMI was calculated as weight (kg)/
height2 (m2). Waist circumference was measured using a
tape measure at the midpoint between the lowest costa
(rib) and the iliac crest of the pelvis. WHtR was calcu-
lated as waist circumference (cm)/height (cm). The per-
centage of body fat (fat mass/total mass × 100) and
appendicular skeletal muscle mass (ASM: the lean soft
tissue masses for the arms and legs) were measured
using DXA (QDR 4500A, Hologic Inc., Waltham, MA,
USA) in mobile examination centers. Following previous
studies, we used the body weight–adjusted appendicular
skeletal muscle mass (ASM) [14].
Blood pressure was measured twice after 5 minutes of
rest, and the average was used for all analyses. After
12 hours of fasting, subjects were tested for blood sugar,
total cholesterol, high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol, and tri-
glyceride levels. Based on a questionnaire that each
subject had completed, he or she was interviewed one-
on-one by a doctor for his/her medical history and
current medications, including for high blood pressure,
diabetes, and hyperlipidemia.
2) Definitions of MS and MHO
Metabolic syndrome was diagnosed if subjects met any
3 of the 5 criteria set by the American Heart Associ-
ation/National Heart, Lung and Blood Institute [15].
The criteria were as follows: (1) waist circumference ≥
90 cm for men, ≥ 80 cm for women; (2) triglyceride ≥
150 mg/dL or taking medication for hyperlipidemia; (3)
HDL cholesterol < 40 mg/dL for men, < 50 mg/dL for
women; (4) blood pressure ≥ 130/85 mmHg or taking
anti-hypertension medication; and (5) fasting blood
sugar ≥ 100 mg/dL or taking medication for diabetes.
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25 kg/m2 and 2 or fewer of the MS criteria, a BMI ≥
25 kg/m2 and at most 1 of the MS criteria, and a
BMI ≥ 25 kg/m2 and none of the MS criteria. Subjects
with MHO were compared with subjects who had a
BMI ≥ 25 kg/m2 and met the diagnostic criteria for MS.
3) Statistical Analysis
All data on continuous and categorical variables are pre-




Education [% (SE)] high to university: ≥10 86.0 (1.3) 74.6 (1.
Income [% (SE)] lowest quartile 10.0 (1.2) 13.4 (1.
Place [% (SE)] Urban 81.2 (2.4) 79.0 (2.
Occupation [% (SE)] Yes 82.3 (1.7) 83.3 (1.
Smoking [% (SE)]
non-smoker 25.9 (1.7) 19.0 (1.
ex-smoker 29.3 (2.0) 34.4 (1.
Current 44.8 (2.0) 46.6 (1.
Alcohol use [% (SE)]
non-drinker 12.2 (1.4) 14.6 (1.
mild to moderate-drinker 68.8 (1.9) 62.6 (1.
heavy-drinker 19.0 (1.6) 22.8 (1.
Exercise [% (SE)] Yes 31.2 (1.8) 25.9 (1.
Age 39.7 ± 0.6 47.5 ± 0
Weight (kg) 78.8 ± 0.3 81.0 ± 0
Height (cm) 171.4 ± 0.3 170.5 ±
BMI 26.8 ± 0.1 27.8 ± 0
Waist circumference (cm) 89.2 ± 0.3 94.4 ± 0
Appendicular muscle mass 31.3 ± 0.1 30.3 ± 0
Body fat (%) 25.3 ± 0.2 26.5 ± 0
WHtR 0.521 0.554
Glucose 94.0 ± 0.6 110.5 ±
Triglyceride* 137.9 ± 3.8 242.9 ±
HDL cholesterol 49.2 ± 0.4 42.6 ± 0
LDL cholesterol 120.4 ± 1.3 113.3 ±
Total cholesterol 192.2 ± 1.4 196.9 ±
Systolic blood pressure 117.0 ± 0.5 125.5 ±
Diastolic blood pressure 77.8 ± 0.4 83.1 ± 0
*p-value after log transformation.
Continuous variables (MEAN ± SE) were compared using t-tests and categorical vari
‘yes’ denotes any form of employment (e.g. excluding the unemployed, homemake
moderate-intensity activity 3 times during a recent week.
BMI, body mass index; WHtR, waist height ratio; BP, blood pressure; MHO, metaboli
metabolic syndrome; MS, metabolic syndrome.These summary statistics take into account the com-
plex sampling design and KNHANES sampling weights,
thereby providing nationally representative prevalence es-
timates. All statistical analyses were performed using SPSS
Statistics, version 21.0 (SPSS Inc, Chicago, USA). The
characteristics of the MHO and MS groups were com-
pared using Student’s t-test for continuous variables and
chi-square test for categorical variables. We used multiple
logistic regression to estimate the odds ratios for MHO
that were associated with various obesity indicators,
adjusting for age, smoking, drinking, and physical activity.FEMALE
p-value MHO MS p-value
759 1145
6) <.0001 61.6 (2.3) 36.0 (1.8) <.0001
3) 0.0384 16.7 (1.9) 29.9 (1.8) <.0001
5) 0.2802 77.9 (3.0) 72.9 (2.9) 0.0678
3) 0.6382 54.1 (2.2) 46.6 (2.0) 0.0121
0.0066 0.5368
4) 89.7 (1.4) 90.7 (1.0)
8) 3.7 (0.8) 4.2 (0.7)
9) 6.6 (1.3) 5.1 (0.8)
0.0777 0.0003
3) 29.5 (2.1) 41.3 (1.9)
9) 67.5 (2.1) 56.2 (1.9)
6) 3.0 (0.7) 2.5 (0.7)
7) 0.0265 28.6(1.9) 25.1 (1.5) 0.1166
.4 <.0001 44.9 ± 0.6 55.4 ± 0.6 <.0001
.4 <.0001 67.0 ± 0.3 67.6 ± 0.4 0.2185
0.3 0.0066 156.8 ± 0.3 154.9 ± 0.2 <.0001
.1 <.0001 27.2 ± 0.1 28.1 ± 0.1 <.0001
.3 <.0001 85.6 ± 0.3 91.0 ± 0.3 <.0001
.1 <.0001 23.9 ± 0.1 23.6 ± 0.1 0.048
.2 <.0001 37.7 ± 0.2 37.7 ± 0.2 0.8175
<.0001 0.546 0.588 0.0007
1.3 <.0001 92.4 ± 0.4 107.9 ± 1.1 <.0001
7.5 <.0001 95.0 ± 1.8 175.0 ± 3.7 <.0001
.4 <.0001 56.4 ± 0.4 46.8 ± 0.3 <.0001
1.4 <.0001 125.1 ± 1.4 121.1 ± 1.2 0.0338
1.4 0.0199 195.5 ± 1.6 198.2 ± 1.4 0.2121
0.6 <.0001 113.6 ± 0.7 128.9 ± 0.6 <.0001
.4 <.0001 73.4 ± 0.5 79.7 ± 0.3 <.0001
ables [% (SE)] were compared using chi-square tests. Regarding occupation,
rs, students, etc.). Regarding exercise, ‘yes’ denotes more than 30 minutes of
cally healthy but obese, defined as a person who satisfies 2 or fewer criteria of
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tor for MHO, we analyzed the receiver operating charac-
teristic (ROC) for each of our three MHO definitions,
and calculated the associated area under the curve
(AUC). ROC analyses were used to assess the diagnostic
performance of the test in terms of its sensitivity and
(1-specificity), for each possible cut-off value of the test.
The AUC of a diagnostic test is a summary statistic for
the overall diagnostic performance of the test. AUCs are
useful measures for a comparing the overall diagnostic
performances of two tests. AUC results are typically cate-
gorized as uninformative (AUC= 0.5), less accurate (0.5 <
AUC ≤ 0.7), moderately accurate (0.7 < AUC ≤ 0.9), or very
accurate (0.9 < AUC < 1) [16]. Values of p < 0.05 were con-
sidered statistically significant.Results
General characteristics of study subjects
The characteristics of the study subjects are presented in
Table 1. Our analysis included 3,770 subjects, all of
whom had a BMI ≥ 25 kg/m2. 56.5% of the subjects were
women. In total, 2,140 subjects (56.8%) met the diagnos-
tic criteria for MS. On the other hand, 46.7% of men
and 39.9% of women met 2 or fewer of the MS criteria
and, accordingly, were assigned to the MHO group. The
MHO group was younger and more educated than the
MS group, both before and after stratifying by gender.
Men in the MHO group were more likely to exercise
regularly exercise and to be non-smokers than were men
in the MS group, but these differences were not evident
for women (Table 1). For women specifically, MHO andTable 2 Adjusted odds ratios for metabolically healthy obesit
indicators and change in MHO percentage, using various obe
BMI WC
% (SE) OR (95% CI) % (SE) OR (95% CI) % (SE)
Men
Q1 69.1 (2.4) ref. 79.0 (2.1) ref. 35.1 (2.7
Q2 54.1 (2.8) 0.77 (0.56,1.05) 59.0 (2.5) 0.71 (0.48,1.05) 51.7 (2.5
Q3 48.1 (2.9) 0.43 (0.31,0.60) 32.7 (2.8) 0.43 (0.31,0.59) 53.0 (2.9
Q4 33.0 (2.4) 0.39 (0.29,0.54) 28.4 (2.4) 0.13 (0.09,0.19) 62.0 (2.6
p for trend <.0001 <.0001 <.0001 <.0001 <.0001
Women
Q1 53.0 (2.9) ref. 70.0 (2.4) ref. 38.3 (2.8
Q2 50.6 (2.7) 0.61 (0.43,0.87) 42.4 (2.7) 0.68 (0.45,1.05) 42.2 (2.7
Q3 36.7 (2.7) 0.32 (0.23,0.46) 30.6 (2.7) 0.46 (0.32,0.64) 44.7 (2.9
Q4 30.7 (2.7) 0.32 (0.22,0.44) 23.9 (2.5) 0.17 (0.12,0.24) 44.4 (2.5
p for trend <.0001 <.0001 <.0001 <.0001 0.076
*MHO was defined as a person who satisfies 2 or fewer criteria of metabolic syndro
Q1, Q2, Q3, and Q4 mean first to fourth quartile respectively. Adjusted by age, smo
BMI, body mass index (kg/m2); WC waist circumference (cm); ASM, weight adjustedMS groups had similar body weights (p = 0.2185) and fat
percentages (p = 0.8175). Mean BMIs were 26.8 kg/m2
and 27.8 kg/m2 for men, and 27.2 kg/m2 and 28.1 kg/m2
for women in the MHO and MS groups, respectively.Associations between MHO and obesity indicators
Among men, lower values of each obesity indicator (BMI,
WC, ASM, fat percentage, and WHtR) were significantly
associated with MHO, as defined by the fulfillment of ≤ 2
criteria for MS (p trend < 0.0001). Among women,
however, the ASM and FP indicators were not signifi-
cantly associated with MHO (p trend = 0.076 and 0.8551,
respectively) (Table 2). Adjusted odds ratios of ASM and
fat percentage for age, smoking, drinking, and physical
activity also failed to show a trend with MHO in
women (p = 0.5331 and 0.9641, respectively), whereas
all indicators were available for assessing MHO in men
(Table 2).Prevalence of MHO, according to different definitions and
ages
As presented in Figure 1, the proportion of MS sub-
ject increased with age among both men and women
(p trend < 0.0001). The prevalence of MHO strongly
depended on its exact definition. Indeed, if the diagnosis
of MHO excluded individuals who met 2 or more criteria
of MS, then 24.5% of male aged 40–49 years would have
MHO. In contrast, if the diagnosis of MHO excluded indi-
viduals who met any criteria of MS, only 6.8% of men aged
40–49 years would have MHO.y (MHO)* according to quartiles of various obesity
sity indicators divided into quartiles
ASM FAT WHtR
OR (95% CI) % (SE) OR (95% CI) % (SE) OR (95% CI)
) ref. 61.1 (2.4) ref. 78.4 (2.0) ref.
) 0.99 (0.74,1.32) 49.4 (2.8) 0.90 (0.66,1.22) 56.4 (2.8) 0.56 (0.39,0.81)
) 1.09 (0.82,1.45) 50.0 (2.9) 1.10 (0.82,1.48) 36.4 (2.8) 0.28 (0.19,0.41)
) 1.28 (0.96,1.72) 43.6 (2.8) 0.96 (0.71,1.32) 23.6 (2.4) 0.12 (0.08,0.17)
<.0001 <.0001 <.0001 <.0001 <.0001
) ref. 43.0 (2.7) ref. 72.9 (2.4) ref.
) 0.88 (0.63,1.23) 39.8 (2.6) 0.92 (0.66,1.27) 42.5 (2.9) 0.61 (0.42,0.90)
) 0.89 (0.64,1.25) 44.8 (2.6) 1.02 (0.76,1.37) 29.7 (2.8) 0.40 (0.28,0.59)
) 0.90 (0.66,1.22) 42.1 (2.9) 0.97 (0.71,1.34) 18.9 (2.1) 0.14 (0.10,0.20)
0.5331 0.8551 0.9641 <.001 <.0001
me. Categorical variables %(SE), analyzed by CHI-Square test.
king, drinking, and physical activity.
appendicular skeletal mass; FAT total body fat (%); WHtR, waist to height ratio.
Figure 1 Proportion of obese patients who have metabolically healthy obesity (MHO) according to age groups with different numbers
(0–5) of MS risks. a. The MHC proportion tends to decrease as age increases. This association remains for each considered definition of
MHO. b. MHO, metabolically healthy but obese; MS, metabolic syndrome. *Data are expressed as %.
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AUCs were calculated to investigate the diagnostic accur-
acy of obesity indicators for MHO (Table 2 and Figure 2).
When MHO was defined by ≤2 criteria of MS, waist cir-
cumference and WHtR had relatively high diagnostic
accuracies for MHO (AUC = 0.7432 and 0.7465 for men,
and AUC= 0.7115 and 0.7409 for women, respectively).
When MHO was defined by the absence of any criteria of
MS, waist circumference and WHtR had even higher diag-
nostic accuracies among both men (AUC = 0.8456 and
0.8239, respectively) and women (AUC = 0.9699 and
0.9436, respectively). Waist circumference and WHtR
were consistently accurate indicators of MHO.
Discussion
Obesity is strongly associated with CVD and diabetes,
but a study has demonstrated that obesity is not inde-
pendently associated with either increased overall mor-
tality or, more specifically, increased CVD mortality [9].Meigs et al.’s findings suggest that the metabolic state of
obese persons is more closely related to disease develop-
ment than is obesity itself. Compared with other forms
of obesity, MHO is metabolically closer to the normal
health state and is associated with a lower risk for CVD
and diabetes. Various studies have reported that the inci-
dence of MHO differs according to race. In a previous
study on Korean adults, the prevalence of MHO was
49.0% [10], which is similar to the 43.2% observed in our
study.
Currently, there is no consensus regarding the criteria
for diagnosing MHO. In several previous studies, MHO
incidence has been assessed based on subsets of the 5
criteria for diagnosing metabolic syndrome, as we have
done here [6,17-20]. Using the same definitions of MHO
as previous reports, we observed that the prevalence of
MHO decreased with age among obese persons; this re-
sult agrees with previous reports [8]. The decreasing
age-specific prevalence of MHO is believed to be a result
Figure 2 (See legend on next page.)
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(See figure on previous page.)
Figure 2 Receiver operating characteristic (ROC) curves for obesity indices. a. Metabolically healthy obesity (MHO) criteria ≤2, b. MHO
criteria ≤1, c. MHO criteria = 0. The blue lines indicate body mass index (BMI), the green lines indicate appendicular skeletal muscle (ASM), the
red lines indicate waist circumference (WC), the purple lines indicate waist to height ratio (WHtR), the brown lines indicate body fat % (FAT), and
the red lines are reference lines. The obesity indices showed different sensitivities and specificities. WC and WHtR were the most sensitive
indicators of MHO, as defined by the fulfillment of MS risk factors = 0 (AUC = 0.846 for WC and 0.824 for WHtR in men, and 0.970 for WC and
0.944 for WHtR in women).
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older ages [21].
Although lifestyle changes and weight loss are com-
monly recommended to individuals with other types of
obesity, it is unclear whether they should be recom-
mended to individuals with MHO. One study showed
that weight reduction in MHO subjects did not lead to
much metabolic improvement, but was associated with
improvements in selected cardio-metabolic risk factors
[22]. It is important to remember that even subjects with
MHO have some dysmetabolic features, such as higher
insulin, insulin resistance, non-HDL cholesterol and
C-reactive protein levels than individuals with normal
weight, as well as lower high-density lipoprotein chol-
esterol (HDL) levels than individuals with normal weight.
Therefore, individuals with MHO also need diet and life-
style interventions [23].
At present, BMI is widely used as a criterion for obes-
ity, although it provides unsatisfactory sufficient assess-
ments of metabolic or health state. Recently, Hung et al.
demonstrated that BMI reflects visceral fat more accur-
ately than does body adiposity index [24]. However, in
this study, we observed that BMI was less accurate than
waist circumference or WHtR in determining MHO. In
addition, although body adiposity index has been shown
to provide a good assessment of body fat percentage
[25], we did not observe this for our results. Our results
show that the female MHO group in our study had body
weights and fat percentages similar to those of the fe-
male MS group. Further, body fat percentage was a less
accurate indicator of metabolic state in obese patients
than was waist circumference or WHtR. It is not surpris-
ing that WC and WHtR predict MHO better than the
other obesity indicators because one of the criteria for
MS is WC, and MHO is defined based on the major cri-
teria of MS. However, we believe that WC and WHtR
offer better predictive performance because the distribu-
tion pattern of excess fat is more closely related to CVD
risk than total fat.
Waist circumference was considered a better measure
of visceral fat than waist to hip ratio [26]. In this study,
we used WHtR rather than waist to hip ratio because
hip circumference was not available. When MHO was
defined as ≤ 2 criteria of MS, both WHtR and waist cir-
cumference were accurate. However, it has also been
reported that anthropometric measurements (includingwaist circumference and WHtR) are not suitable markers
of deteriorated lipid profiles in severe obesity (BMI >
40 kg/m2) [27]. Although we attempted to analyze the
subgroup of subjects with BMI > 35 kg/m2, we could not
find similar results because of small number of subjects
(n = 52).
WHtR is known to be a risk factor for arteriosclerosis
[28], and has been reported to be a better predictor of
CVD than waist circumference, especially in men [29].
However, in our study, waist circumference was not in-
ferior to WHtR as a predictor of MS, including after
stratifying by gender and for most levels of metabolic
risks.
In clinical practice, MS is diagnosed on the basis of body
measurements such as height, weight, waist circumfer-
ence, and blood pressure and laboratory tests such as lipid
and blood sugar. However, our results indicated that even
simple body measurements can be used to accurately pre-
dict the metabolic state of obese patients. This may be ad-
vantageous because body measurements are faster and
less costly.
In this study, insulin sensitivity was not a criterion for
diagnosing MHO, which is a potential limitation of our
research; however, we attempted to minimize this error
by including fasting blood sugar and the use of diabetes
medication. Our findings are limited to the Asian popu-
lation and should be confirmed in other ethnic groups
and regions. However, the KNHANES study sample that
we used was large and nationally representative, includ-
ing several years of data and numerous covariates.
Conclusions
The results of this study demonstrate that waist circum-
ference and WHtR can serve as important indicators of
metabolic status for persons who have been classified as
obese based on their BMIs. Additional research is needed
on obesity indicators for MHO. It is essential to obtain a
consensus definition of MHO, establish diagnosis criteria,
and provide additional methods for distinguishing MHO
from other forms of obesity.
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